secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2021-09-27T23:59:59+00:00
Accession:  0001493152-21-023805
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Founder, CMO & director Dr. Singh takes 12-month sabbatical; resigns from board
-------------------------------------------------------------------------------

- Sabbatical effective Sept 1, 2021 for 12 months; compensation and benefits unchanged.
- Dr. Singh resigned from board of directors effective Sept 22, 2021.
- Duties reduced to advising on clinical studies, device development, and conferences.
- Board may reinstate or modify duties 30 days before sabbatical ends; extension possible.
- Company believes sabbatical will not impact operations; ties to Stanford seen as growth opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315221023805/0001493152-21-023805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315221023805/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-023805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer